RESEARCH PAPER

Natural Bioactive Compounds in Drug Discovery: Molecular Basis, Anticancer Mechanisms and Translational Hurdles

Triveni Digarse[1*], Deepika Ahlawat[2], Priyanka Thakur[3], Pooja Pradeep Gujar[4], Sweta Bawari[5], Seema Bahuguna[6], Chakresh Patley[7]

[1]Oriental College of Pharmacy, Raisen Road, Bhopal, Madhya Pradesh- 462022.
[2]ICFAI School of Pharmaceutical Sciences, ICFAI University, Jaipur, Rajasthan- 302015.
[3]Department of Pharmacology, University School of Pharmaceutical Sciences, Rayat Bahra University, Mohali, Punjab-140103.
[4]Nagpur College of Pharmacy Wanadongri, Nagpur, Maharashtra-441110.
[5]Amity Institute of Pharmacy, Amity University Campus, Sector-125, Noida, Gautam Buddha Nagar, Uttar Pradesh-201301.
[6]JBIT College Of Pharmacy, Dehradun, Uttarakhand-248197.
[7]Oxford Group of Institution, Haridwar, Uttarakhand- 249403.

***Corresponding Author :** TriveniDigarse,trivenidigarse21@gmail.com, priyanka123thakur123@gmail.com

---

ABSTRACT

Cancer is major current health concern worldwide so various novel treatments are required. Phytochemical's a bioactive non-nutrient compounds derived from plants that demonstrate significant potential in both cancer chemo prevention and therapeutic intervention. These compounds exert their profound biological effects through a mechanism described as poly pharmacology, concurrently modulating multiple signal transduction pathways critical to cancer pathogenesis, including the PI3K/Akt/mTOR, NF-κB, and Wnt β-catenin axes. Their primary anti-cancer actions involve the inhibition of cell proliferation, induction of targeted apoptosis, and interference with metastasis and angiogenesis. Furthermore, phytochemical show promising synergistic effects when combined with conventional chemo- and radiotherapy, enhancing therapeutic efficacy and mitigating side effects. Despite compelling preclinical evidence demonstrating their low intrinsic toxicity and potent mechanistic action, a significant challenge remains in their clinical translation, primarily due to poor aqueous solubility and resulting low oral bioavailability. Overcoming this pharmacokinetic bottleneck necessitates the advanced application of nanotechnology-based drug delivery systems, such as nanoparticles and liposomes, to achieve effective concentrations at tumors sites.

Keywords: Cancer; Phytochemicals; Apoptosis; Cell cycle; Molecules Target; DNA integrity.
How to cite this article: Digarse T, Ahlawat D, Thakur P, Gujar PP, Bawari S, Bahuguna S, Patley C. Natural Bioactive Compounds in Drug Discovery: Molecular Basis, Anticancer Mechanisms and Translational Hurdles. Int J Drug Deliv Technol. 2026;16(69s):1590-1600. DOI: 10.25258/ijddt.16.69s.154

1. Introduction to Phytochemical Oncology and Classification

Phytochemical oncology is that branch that deals with plants derived compounds which provide preventive or supportive treatment option. Plants derived components aid by triggering cell specific apoptosis, halt angiogenesis, alters the hormonal concentrations or sensitize the tumor cell specific receptor to chemotherapeutic drugs. Recent work revealed the mechanistic claim to direct the cancer stem cell using preclinical and human trial. Phytochemicals are categorized into five group's i.e. phenolic compounds, alkaloids, terpenes, organ sulfur compounds, phytosterols, carotenoids, organosulfur compounds, saponins, lignans and proanthocyanidins etc. These agents basically work by halting G1/S phase, activate mitochondrial pathways, caspases, block NF-Kb, MAPK, GLUT-2, CYP1B1 etc. It affect DNA methylation, miRNA expression.

1.1 Bioactive Non-Nutrient Compounds

Phytochemical's constitute a diverse group of compounds originating from plants that are not essential nutrients but possess bioactive properties highly connected to the reduction of major chronic disease risk, including cancer.[1] The utilization of plant-derived compounds in cancer prevention, known as chemo prevention, is supported by strong rationale.[1] Phytochemical's are capable of stopping, postponing, or reversing carcinogenesis during its complex stages of initiation, promotion, and progression.[1]

A fundamental aspect of their protective role involves counteracting oxidative stress, which plays a vital role in the pathogenesis of many cancers.[7] Dietary antioxidant phytochemical are abundant in plants and are capable of exerting various mechanisms of action against tumors.[7] The comprehensive influence of these agents extends beyond simple antioxidant capacity to modulate critical cancer hallmarks, such as reducing inflammation, slowing the aging process, impairing proteostasis, and inhibiting tumor development.[8] This capability to influence multiple risk factors suggests that

they are powerful tools against the large proportion of sporadic malignancies that are linked to diet and lifestyle.[9]

1.2 Historical Context: Clinically Approved Plant-Derived Agents

The field of phytotherapy is firmly established in clinical oncology, evidenced by the fact that several complex, highly effective plant-derived compounds are already integral to modern cancer treatment protocols. Four major classes of these clinically used anti-cancer compounds include vinca alkaloids, taxane diterpenoids, camptothecin derivatives, and epipodophyllotoxin.[5] The success of these compounds, which interfere with fundamental cellular machinery like DNA topology and the mitotic spindle, established a critical precedent for the therapeutic potential inherent in plant chemistry.The anti-cancer phytochemical's described in the text are derived from a diverse spectrum of botanical sources, ranging from endangered medicinal species to common dietary vegetables. The clinically established vinca alkaloids are extracted from the aerial parts of the Madagascar Periwinkle (Catharanthus roseus), while taxane diterpenoids originate from the genus Taxus, specifically the bark of the Pacific Yew (Taxus brevifolia) and the needles of the European Yew (Taxus baccata).Camptothecin derivatives are sourced from the "Happy Tree" (Camptotheca acuminata), and epipodophyllotoxins are isolated from the rhizomes of Mayapple species, such as Podophyllum peltatum and the Himalayan Sinopodophyllum hexandrum.Regarding dietary compounds, the flavonoid Apigenin is highly concentrated in Parsley (Petroselinum crispum) and Celery (Apium graveolens), while Resveratrol is predominantly found in the skins of Grapes (Vitis spp.). The carotenoids Lycopene and \beta-carotene are extracted from Tomatoes (Solanum lycopersicum) and Carrots (Daucus carota), respectively. Within the terpenoid class, Thymol is derived from Thyme (Thymus vulgaris), Menthol from Peppermint (Mentha x piperita), and Auraptene from the peel of Citrus fruits like grapefruit and orange. Finally, Organosulfur Compounds are abundant in Garlic (Allium sativum) and Onions (Allium cepa), as well as in cruciferous vegetables like Broccoli (Brassica oleracea var. italica) and Chinese cabbage (*Brassica rapa*).

1.3 Classification of Key Anti-Cancer Phytochemical Classes

Phytochemicals are broadly classified based on their chemical structure, yielding diverse groups with distinct biological properties.

1.3.1 Polyphenolic Compounds

Polyphenolic's are secondary metabolites extensively found in fruits and other plant sources.[1] They represent a major category of dietary antioxidant phytochemicals.[8] They are broadly categorised into two main groups: flavonoids and non-flavonoids.[8]

- **Flavonoids:** This large subgroup includes compounds such as Epigallocatechin gallate (EGCG) found in green tea [11] and Apigenin.[13] Flavonoids, as potent antioxidants, have been studied for their anti-proliferative activity, particularly in breast cancer.[2]
- **Non-Flavonoids:** This diverse category includes phenolic acids, lignans, tannins, and stilbenes.[8] Phenolic acids stand out as the most prevalent category, defined by aromatic rings linked to organic acids.[8] Stilbenes, such as Resveratrol, contain a 1,2-diphenylethylene nucleus and are known for their ability to reduce tumorigenesis at all stages of carcinogenesis.[14]

1.3.2 Terpenoids and Carotenoids

- **Carotenoids:** These are the most extensive natural pigments, gaining attention for their provitamin and antioxidant properties (e.g., Lycopene and β-carotenoid).[1] Carotenoids exert direct antitumor effects by regulating cell cycle progression and inducing apoptosis.[16]
- **Terpenoids:** This class includes various compounds, such as Thymol, Menthol, and Auraptene, which demonstrate anti-cancer effects via mechanisms such as cell cycle arrest and mitochondrial depolarization.[17] Taxanes are a major diterpenoid class already utilized clinically.[10]

1.3.3 Alkaloids and Organosulfur Compounds (OSCs)

- **Alkaloids:** These nitrogen-containing compounds are widely studied for their varied biological activities.[1] Vinca alkaloids and camptothecin derivatives are examples already in clinical use.[10]
- **Organosulfur Compounds:** OSCs are recognized for their sulfur-containing functional groups and are abundant in cruciferous vegetables (e.g., broccoli, Chinese cabbage) and members of the *Allium* genus.[1] Diallyl disulfide, for instance, has been assessed for its ability to prevent N-nitrosodiethylamine-stimulated carcinogenesis.[1]

Table - 1: Classifications and Sources of Key Anti-Cancer Phytochemical Classes

Phytochemical Class	Key Subgroups/Examples	Primary Sources	Reference
Polyphenolic Compounds	Flavonoids (Apigenin, EGCG), Non-Flavonids (Resveratrol, Phenolic Acids)	Fruits, Green Tea, General Plant Sources	[14], [7]
Terpenoids and Carotenoids	Carotenoids (Lycopene, β-carotenoid), Terpenoids (Thymol, Menthol, Taxanes)	Natural Pigments, Fruits, Various Plants	[30]
Alkaloid and Organosulfur Compounds	Alkaloids (Vinca Alkaloids, Camptothecin Derivatives), Organosulfur Compounds (Diallyl disulphide)	Nitrogen-containing plants, Cruciferous and Allium vegetables	[39]

2. Molecular Mechanisms of Anti-Cancer Action

The anti-cancer effectiveness of phytochemicals is largely attributed to their capacity to influence numerous signaling pathways concurrently, a key feature known as polypharmacology.[4] This multi-targeted action allows them to interfere with the complex, redundant mechanisms of cancer cells.



Fig. 1 : Cellular Mechanism of Plant Based Anticancer agents

2.1 Orchestrating Cell Death: Apoptosis and Cell Cycle Arrest

2.1.1 Induction of Apoptosis (Programmed Cell Death)

Phytochemicals accelerate the necessary cellular defense mechanisms by actively inducing programmed cell death.[7] This cell death can be triggered through both the intrinsic (mitochondria-dependent) and extrinsic (death receptor-mediated) apoptotic pathways.[18]

The **intrinsic pathway** is commonly triggered by physical and chemical inputs, such as stress signals and growth factor shortages.[19] This leads to mitochondrial depolarization and the release of hydrolytic enzymes into the cytosol.[19] Mechanistically, phytochemicals modulate the Bcl-2 family of proteins, typically decreasing anti-apoptotic proteins like Bcl-2 and Bcl-xl while increasing pro-apoptotic proteins such as Bax.[19] For instance, the carcinogenic glycoside oleandrin induces apoptosis by generating reactive oxygen species (ROS) and damaging mitochondrial membrane potential, regulating the Bcl-2 level and activating Caspases 9, 8, and 3.[19] The release of cytochrome c combines with Apaf-1 and procaspase-9 to form an apoptosome, activating the execution pathway.[18]

The **extrinsic pathway** involves cell surface receptors but connects to the intrinsic pathway via activated caspase-8, which regulates the pro-apoptotic protein BID.[18]

2.1.2 Cell Cycle Modulation and DNA Integrity

Phytochemicals seize cancer cells from further growth by inducing cell cycle arrest at critical checkpoints (G0/G1, G1/S, G2/M, and M phase), often followed by irreparable DNA damage.[21]

Specific examples include the terpenoid Thymol, which induces anti-cancer effects by arresting the cell cycle at the G0/G1 phase in acute promyelocytic leukemia cells

(HL-60).[17] Apigenin also promotes cell cycle arrest alongside stimulating apoptotic death.[13]

Furthermore, several plant-derived drugs exert direct genotoxic effects. Camptothecin, for example, binds to DNA and topoisomerase II, forming a ternary complex. This action prevents the re-ligation process, thereby causing DNA damage and initiating apoptotic pathways.[20] Similarly, Menthol triggers DNA damage and subsequent cell death in gastric cancer cells by reducing topoisomerase I and II levels.[17] Taxol, a diterpene, inhibits cell division by stabilizing microtubules during spindle fiber formation (M phase), impeding the cell's entry into the S phase.[19]

2.2 Inhibition of Angiogenesis, Invasion, and Metastasis

Phytochemicals are crucial regulators of the processes required for tumors to grow beyond microscopic size and spread throughout the body.

2.2.1 Anti-Angiogenesis

The formation of new blood vessels (angiogenesis) is essential for tumors to acquire oxygen and nutrients. Phytochemicals frequently exhibit anti-angiogenetic effects, often indirectly by modulating signaling molecules.[23] Resveratrol is a well-documented example, shown to suppress vascular endothelial growth factor (VEGF) expression by inhibiting hypoxia-inducible factor 1-alpha (HIF-1α).[3] VEGF is a primary target in halting the tumor's blood supply, and the down-regulation of inflammatory cytokines also contributes to anti-angiogenesis.[3]

2.2.2 Anti-Metastatic Activity and EMT Regulation

Phytochemicals interfere with the metastatic cascade by modulating key enzymes involved in tissue remodeling and invasion, such as matrix metalloproteinases (MMPs).[11] Curcumin, a notable agent, downregulates angiogenic genes, including MMP-9 and MMP-3.[7] Certain extracts are known to inhibit adhesion, invasion, metastasis, and the activity of MMP-2 and MMP-9.[24]

A critical target is the Epithelial-Mesenchymal Transition (EMT), a process where epithelial cells acquire a migratory mesenchymal phenotype, enabling invasion and metastasis.[25] EMT is governed by pathways like Wnt and PI3K/FAK.[25] Phytochemicals can disrupt these pathways, effectively suppressing or reversing the EMT process, thus interfering with malignant cell metastasis and drug resistance.[25]

2.3 Epigenetic and Genomic Targets

The activity of phytochemicals extends to the genomic level, demonstrating an ability to modify genetic and epigenetic targets associated with cancer prevention and therapy.[12] These compounds can modulate epigenetic alterations, such as DNA methylation and the expression patterns of microRNAs (miRNAs).[11] This influence on gene expression—specifically regulating cell survival, proliferation, and differentiation—indicates that phytochemical actions are not limited to immediate cytotoxicity but involve long-term regulatory control over cellular fate.[11]

3. Targeting Oncogenic Signal Transduction Pathways

The functional strength of phytochemicals lies in their capacity for simultaneous pathway inhibition, a characteristic that differentiates them from conventional single-target drugs. This strategic multi-targeting inhibits the common molecular escape mechanisms utilized by cancer cells.

3.1 Modulation of the PI3K/Akt/mTOR Axis

The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR signaling pathway is a central axis governing essential cellular functions, including survival, growth, proliferation, and cell cycle progression.[26] Its aberrant activation is a hallmark of many cancers.[27]

Inhibition of this pathway is a major therapeutic goal. Curcumin, for instance, exhibits strong anti-cancer effects by inhibiting c-Met activation and subsequently suppressing the PI3K/Akt/mTOR signaling pathway, leading to the inhibition of EMT.[26] Furthermore, the PI3K/Akt/mTOR pathway is intimately involved in regulating autophagy, a cellular self-defense mechanism where irregular cell proliferation is suppressed.[7] Phytochemicals like Curcumin and ursolic acid promote this protective autophagy by downregulating the Akt/mTOR signaling pathway.[7] This ability to exert dual control—inhibiting critical cell survival signals while simultaneously stimulating pro-death mechanisms like autophagy—underscores the efficiency of these natural compounds as potent cellular modulators.[7]

3.2 Targeting Inflammation: NF- κB and STAT3

Chronic inflammation is a powerful driver of tumor initiation and progression. Phytochemicals offer critical intervention points by suppressing inflammatory signaling pathways.

The transcription factors Nuclear Factor-kappa B (NF-κB) and Signal Transducer and Activator of Transcription 3 (STAT3) largely act as pro-carcinogenesis factors. Their activation promotes cell proliferation, resistance to apoptosis, angiogenesis, and metastasis.[3] Phytochemicals exert anti-cancer effects by specifically suppressing NF-κB activation, inhibiting STAT3 activation, and down-regulating inflammatory enzymes like Cyclooxygenase-2 (COX-2).[3] For instance, Apigenin inhibits the progression of prostate cancer by targeting the NF-κB pathway.[13] Similarly,

Resveratrol inhibits ovarian carcinogenesis by downregulating NF-κB activity, alongside suppressing HIF-1α and VEGF expression.[3] By modulating these inflammatory components, phytochemicals serve as highly effective chemopreventive agents, addressing the crucial link between inflammation and oncogenesis.[3]

3.3 Elimination of Cancer Stem Cells (CSCs) via Wnt/ β-Catenin

A profound strategic advantage offered by certain phytochemicals is their ability to eliminate Cancer Stem Cells (CSCs). CSCs represent a small, highly malignant subpopulation within tumors responsible for drug resistance, recurrence, and metastasis.[28]

The elimination of CSCs is exemplified by Sulforaphane, a bioactive isothiocyanate derived from broccoli.[29] Studies utilizing xenograft models in immunodeficient mice demonstrated that Sulforaphane eliminated breast CSCs *in vivo*, preventing subsequent tumor formation when the primary cells were reimplanted in recipient mice.[29] Evidence supporting this efficacy was determined by the Mammosphere Formation Assay and the Aldefluor Assay, which showed Sulforaphane preferentially inhibited tumor-initiating stem/progenitor cells at concentrations that had only minimal effects on the bulk tumor cell population.[29]

The identified mechanism for this selective activity is the **downregulation of the Wnt/β-catenin self-renewal pathway**.[29] The Wnt pathway is a crucial driver of stemness and is involved in inducing EMT.[25] By specifically inhibiting this self-renewal pathway, Sulforaphane addresses the root cause of treatment failure and relapse. This targeted elimination of the drug-resistant CSC subpopulation positions phytochemicals as ideal complementary agents in combination protocols, where conventional chemotherapy can destroy the bulk tumor while the phytochemical eliminates the residual, highly malignant CSCs.[28]

Table- 2 : Molecular Targeting and Mechanistic Specificity of Key Agents

Phytochemical	Primary Target Pathway/Mechanism	Specific Molecular Action	Outcome/ Efficacy Example	Reference
Curcumin	PI3K/ Akt/mTOR, NF-κB, c-Met	Inhibition of pathway activation, Autophagy promotion, Downregulation of MDR-1 [7]	Enhanced chemo-sensitivity, Suppression of EMT [30]	[30], [7]
Sulforaphane	Wnt/β-Catenin Pathway (CSCs)	Downregulation of self-renewal transcription factors	Selective elimination of breast Cancer Stem Cells *in vivo* [29]	[29]
Resveratrol	NF-κB, HIF-1α, VEGF	Suppression of inflammatory transcription factors, Inhibition of angiogenesi [3]	Inhibition of ovarian carcinogenesis [3]	[3]

Apigenin	PI3K/Akt, NF-κB	Stimulates apoptotic cell death and cell cycle arrest [13]	Chemopreventive effects in prostate cancer [13]	[13]
EGCG	Bcl-xl, EGFR signaling	Binds and inhibits anti-apoptotic proteins [31]	Induction of apoptosis, Suppression of proliferation [31]	[31]

4. Translational Evidence and Clinical Status

4.1 Preclinical Evidence and Epidemiological Correlation

Preclinical investigations have provided substantial evidence supporting the anti-cancer potential of phytochemicals. Numerous *in vitro* studies report strong cancer cell inhibition mediated through DNA damage and the activation of apoptosis-inducing enzymes.[32] *In vivo* studies using animal models have also yielded remarkable results in inhibiting tumor development and progression.[2]

Epidemiological evidence supports the general concept of dietary chemoprevention, showing an inverse correlation between the regular consumption of fruits and vegetables and cancer incidence.[9] The intake of specific compounds, such as isothiocyanates and indole-3-carbinol, appears to reduce the risk of tumors in sites like the breast, stomach, colorectal region, and prostate.[33] However, it is essential to note that while overall dietary patterns are protective, the epidemiological data supporting the efficacy of many specific, isolated phytochemicals remains inconclusive, necessitating caution and further research.[9]

4.2 Clinical Trial Outcomes for Key Phytochemicals

Clinical trials involving phytochemicals are focused on three major objectives: enhancing the response of cancer cells to standard chemo- and radiotherapy, mitigating the severe adverse effects associated with conventional cancer therapy, and rigorously monitoring for potential negative drug interactions.[5] Leading agents with the most satisfactory clinical support include Curcumin, Resveratrol, Green Tea extracts (EGCG), and *Viscum album*.[5]

Curcumin, in particular, has demonstrated promising results as an adjunct therapy. Clinical trials confirm its safety and tolerability when administered orally alongside conventional regimens.[35] In an open-label Phase II trial for pancreatic cancer patients, the concurrent administration of high-dose oral Curcumin (up to 8,000 mg/day) with Gemcitabine chemotherapy achieved an overall disease control rate of 61.4% (27.3% partial responses and 34.1% stable disease).[35] Furthermore, Curcumin was found to be safe and tolerable when combined daily with FOLFOX chemotherapy in patients with colorectal liver metastasis (CRLM).[35] Preclinical studies help explain this synergy, showing Curcumin enhances the sensitivity of cancer cells to cisplatin and reduces acquired resistance to paclitaxel by down regulating the multi-drug resistance gene MDR-1.[30]

Despite the strong mechanistic evidence, a prevailing limitation in translation is that the amounts of phytochemicals required to exert robust chemo preventive effects often exceed levels achievable through normal dietary consumption.[9]

4.3 Synergistic Potential with Conventional Therapy

The concept of combining phytochemicals with standard conventional treatments leverages their capacity to modulate multiple pathways, effectively functioning as chemo-sensitizers.[36] Combined efficacy can be additive (equivalent to the sum of individual effects) or, more favorably, synergistic (greater than the sum of individual effects).[38]

Preclinical studies have already established the synergistic or additive effects of various combinations, such as berberine, curcumin, EGCG, and sulforaphane, with chemotherapeutic agents, often demonstrating acceptable side effects.[5] This combination strategy is particularly vital in cancers with poor prognoses, such as lung cancer, where natural compounds show potential in overcoming chemo resistance and enhancing overall therapeutic actions.[39] Moreover, phytochemicals often protect non-cancerous cells from chemotherapy-induced side effects, lowering the total required dose frequency and toxicity of standard agents.[36]

Table -3: Summary of Clinical and Translational Evidence

Phytochemical Agent	Cancer Type/ Focus	Trial Phase/ Context	Key Finding/ Clinical Outcome	Reference
Curcumin	Pancreatic Cancer, CRLM	Phase I/II (Adjunct to Gemcitabine/FOLFOX)	Safe, tolerable adjunct therapy; documented partial responses and stable disease	[35]
Green Tea (EGCG)	Various	Epidemiological / Clinical	Associated with modified (reduced) cancer risk, strong chemopreventive potential	[9]
Viscum album	Various	Clinical	Reported beneficial effects on cancer-related symptoms and quality of life	[34]
Phytosterols	Multiple Cancer Risk Factors	Epidemiological / In Vitro	Proven to lower multiple cancer risk factors (e.g., obesity, inflammation)	[15]
Phytochemicals in Combination	Various	Preclinical / Early Clinical	Demonstrate synergistic or additive effects, enhancing chemo-efficacy	[5]

5. Pharmacological Challenges and Translational Strategies



Fig. 3 : Synergistic Output of Phytogenic Novel Anticancer Drug Delivery

5.1 The Bioavailability Bottleneck

Despite robust demonstration of molecular mechanisms in vitro and promising results in animal models, the clinical translation of many phytochemicals faces a critical barrier: poor pharmacokinetics.6 Compounds like Curcumin, EGCG, and Resveratrol often possess low aqueous solubility, which severely limits their oral bioavailability and prevents them from reaching the necessary therapeutic concentrations at the tumor site.6 The therapeutic efficacy of an anticancer agent relies intrinsically on its ability to circulate and concentrate sufficiently at the target tissue.6 Without adequate delivery, the sophisticated molecular effects observed in the laboratory cannot be replicated in vivo using standard delivery methods.

5.2 Advanced Nanotechnology-Based Drug Delivery Systems

The emergence of novel drug delivery systems is critical to overcoming the poor biopharmaceutical properties of phytochemicals, offering a promising approach to enhance bioavailability while minimizing systemic toxicity.[6] The strategic focus shifts from merely identifying new compounds to engineering their optimal delivery vehicle.

5.2.1 Nanoparticles (NPs)

Nanoparticles are sub-micron-sized colloidal systems formulated from various polymers.[6] They offer significant advantages, including protecting the encapsulated drug from chemical and enzymatic degradation, improving solubility, and allowing for sustained drug release.[6] The small size and unique physical properties of NPs enable passive targeting of tumors through the Enhanced Permeability and Retention (EPR) effect. Furthermore, NPs can be actively targeted by conjugating specific ligands (such as peptides or antibodies) to their surface, facilitating site-specific internalization.[6] Nanoparticle encapsulation has been extensively explored for Curcumin, resulting in "nanocurcumin," and for EGCG and Naringenin, dramatically enhancing their bioavailability and therapeutic efficacy in experimental models.[6]

5.2.2 Liposomes

Liposomes are versatile spherical vesicles composed of phospholipid bilayers, capable of encapsulating both hydrophilic and lipophilic compounds.[6] They possess low immunogenicity, high biocompatibility, and biodegradability. Liposomes improve therapeutic efficacy and reduce side effects by altering drug pharmacokinetics and biodistribution, protecting the active compound from premature degradation.[6] Surface modification with polyethylene glycol (PEG) results in "Stealth Liposomes," which successfully prolong their circulation half-life. Liposomal formulations of Curcumin and Quercetin have been shown to increase aqueous solubility and bioavailability, resulting in enhanced apoptosis induction *in vitro* and more efficient tumor growth inhibition *in vivo* compared to the free compounds.[6] In this new translational paradigm, the delivery system itself becomes an intrinsic part of the therapeutic strategy.

5.3 Safety Profile and Future Directions

A major advantage of phytochemicals is their generally low intrinsic toxicity to normal cells, distinguishing them favorably from conventional cytotoxic chemotherapy.[5] This low toxicity profile makes them particularly attractive for long-term chemoprevention strategies.

Future research efforts must urgently focus on bridging the gap between strong preclinical data and established clinical validation.[15] This requires a significant increase in well-designed human studies and clinical trials, with careful attention paid to safety measures and effective dosing.[15] Given the promising initial results, combinations of anti-cancer phytochemicals—potentially delivered through engineered Nano carriers—are warranted, as herbal preparations containing multiple phytochemicals are believed to yield greater therapeutic effects than the equivalent dosage of isolated compounds.[34]

6. Conclusion

Phytochemicals represent a viable and biologically complex source for cancer management. Scientific evidence strongly supports their capacity to function as potent chemo preventive and therapeutic agents by moving beyond simple antioxidant roles to execute targeted, polypharmacological inhibition of critical oncogenic processes. Key mechanisms include the

induction of apoptosis via mitochondrial pathways, the disruption of cell cycle progression, the suppression of inflammatory pathways (NF-κB, STAT3), and, most critically, the selective elimination of treatment-resistant Cancer Stem Cells via pathways like Wnt/β-catenin. The ultimate clinical success of these promising natural products, however, relies not only on their intrinsic biological activity but overwhelmingly on optimizing their pharmacokinetic properties. Innovative drug delivery technologies, such as nanoparticles and liposomes, are essential tools for overcoming the bioavailability bottleneck, maximizing the synergistic potential with conventional therapies, and translating robust preclinical insights into validated clinical outcomes for cancer patients.

References

1. Meybodi, N. M., Mortazavian, A. M., Monfared, A. B., Sohrabvandi, S., & Meybodi, F. A. (2017). Phytochemicals in cancer prevention: a review of the evidence. *Iranian Journal of Cancer Prevention*, *10*(1)

2. George, B. P., Chandran, R., & Abrahamse, H. (2021). Role of phytochemicals in cancer chemoprevention: Insights. *Antioxidants*, *10*(9), 1455.

3. Sadiq, S. C., Joy, M. P., Aiswarya, S. U., Ajmani, A., Keerthana, C. K., Rayginia, T.P., .. & Anto, R. J. (2024). Unlocking nature's pharmacy: an in-depth exploration of phytochemicals as potential sources of anti-cancer and anti-inflammatory molecules. Exploration of Drug Science, 2(6), 744-784.

4. Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020). Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Frontiers in pharmacology, 10, 1614.

5. Kamran, S., Sinniah, A., Abdulghani, M. A., & Alshawsh, M. A. (2022). Therapeutic potential of certain terpenoids as anticancer agents: a scoping review. *Cancers*, *14*(5), 1100.

6. Baeza-Morales, A., Medina-Garcia, M., Martinez-Peinado, P., Pascual-Garcia, S., Pujalte-Satorre, C., Lopez-Jaen, A. B., & Sempere-Ortells, J. M. (2024). The antitumour mechanisms of carotenoids: a comprehensive review. *Antioxidants*, *13*(9), 1060.

7. Briguglio, G., Costa, C., Pollicino, M., Giambò, F., Catania, S., & Fenga, C. (2020). Polyphenols in cancer prevention: New insights. *International Journal of Functional Nutrition*, *1*(2), 9.

8. Khan, T., Ali, M., Khan, A., Nisar, P., Jan, S. A., Afridi, S., & Shinwari, Z. K. (2019). Anticancer plants: A review of the active phytochemicals, applications in animal models, and regulatory aspects. *Biomolecules*, *10*(1), 47.

9. Hosseini, A., & Ghorbani, A. (2015). Cancer therapy with phytochemicals: evidence from clinical studies. *Avicenna journal of phytomedicine*, *5*(2), 84.

10. Rudzińska, A., Juchaniuk, P., Oberda, J., Wiśniewska, J., Wojdan, W., Szklener, K., & Mańdziuk, S. (2023). Phytochemicals in cancer treatment and cancer prevention—review on epidemiological data and clinical trials. *Nutrients*, *15*(8), 1896.

11. Wali, A. F., Pillai, J. R., Talath, S., Shivappa, P., Sridhar, S. B., El-Tanani, M., ... & Al Ani, N. N. (2025). Phytochemicals in Breast Cancer Prevention and Treatment: A Comprehensive Review. *Current Issues in Molecular Biology*, *47*(1), 30.

12. Situmorang, P. C., Ilyas, S., Nugraha, S. E., Syahputra, R. A., & Nik Abd Rahman, N. M. A. (2024). Prospects of compounds of herbal plants as anticancer agents: a comprehensive review from molecular pathways. *Frontiers in Pharmacology*, *15*, 1387866.

13. Situmorang, P. C., Ilyas, S., Nugraha, S. E., Syahputra, R. A., & Nik Abd Rahman, N. M. A. (2024). Prospects of compounds of herbal plants as anticancer agents: a comprehensive review from molecular pathways. *Frontiers in Pharmacology*, *15*, 1387866

14. Majrashi, T. A., Alshehri, S. A., Alsayari, A., Muhsinah, A. B., Alrouji, M., Alshahrani, A. M., ... & Atiya, A. (2023). Insight into the biological roles and mechanisms of phytochemicals in different types of cancer: targeting cancer therapeutics. *Nutrients*, *15*(7), 1704.

15. Wani, A. K., Akhtar, N., Mir, T. U. G., Singh, R., Jha, P. K., Mallik, S. K., ... & Prakash, A. (2023). Targeting apoptotic pathway of cancer cells with phytochemicals and plant-based nanomaterials. *Biomolecules*, *13*(2), 194.

16. Chaudhry, G. E. S., Md Akim, A., Sung, Y. Y., & Sifzizul, T. M. T. (2022). Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. *Frontiers in pharmacology*, *13*, 842376.

17. Wani, A. K., Akhtar, N., Mir, T. U. G., Singh, R., Jha, P. K., Mallik, S. K., ... & Prakash, A. (2023). Targeting apoptotic pathway of cancer cells with phytochemicals and plant-based nanomaterials. *Biomolecules*, *13*(2), 194.

18. Rahman, M. A., Hannan, M. A., Dash, R., Rahman, M. H., Islam, R., Uddin, M. J., & Rhim, H. (2021). Phytochemicals as a complement to cancer chemotherapy: Pharmacological modulation of the autophagy-apoptosis pathway. *Frontiers in Pharmacology*, *12*, 639628.

19. Sajad Fakhri, Seyed Zachariah Moradi, Akram Yarmohammdi, Fatemeh Narimani, Carly E. Wallace, Anupam Bishayee (2022). Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy. *Frontiers in oncology, 10, 834072.*

20. Suvarna, V., Murahari, M., Khan, T., Chaubey, P., & Sangave, P. (2017). Phytochemicals and PI3K inhibitors in Cancer—an insight. *Frontiers in Pharmacology*, *8*, 916.

21. Pandey, P., Lakhanpal, S., Mahmood, D., Kang, H. N., Kim, B., Kang, S., & Kim, B. (2025). An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway. *Frontiers in Pharmacology*, *15*, 1513422.

22. Jang, J. H., & Lee, T. J. (2023). Mechanisms of phytochemicals in anti-inflammatory and anti-cancer. *International Journal of Molecular Sciences*, *24*(9), 7863.

23. Aldeeb, I., Joseph, J., Majid, A. M. S. A., & Samad, N. A. (2021). Phytochemicals with Direct and/or Indirect Anti-angiogenic Properties against Various Cancer Types Focusing on Their Mechanism of Action. *Journal of Angiotherapy*, *5*(1), 226-233.

24. Kim, M. K., Kim, K., Han, J. Y., Lim, J. M., & Song, Y. S. (2011). Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. *Genes & nutrition*, *6*(2), 109-115.

25. Liu, S., Li, L., & Ren, D. (2023). Anti-cancer potential of phytochemicals: The regulation of the epithelial-mesenchymal transition. *Molecules*, *28*(13), 5069.

26. Jain, A., Madu, C. O., & Lu, Y. (2021). Phytochemicals in chemoprevention: a cost-effective complementary approach. *Journal of Cancer*, *12*(12), 3686.

27. Aqil, F., Munagala, R., Jeyabalan, J., & Vadhanam, M. V. (2013). Bioavailability of phytochemicals and its enhancement by drug delivery systems. *Cancer letters*, *334*(1), 133-141.

28. Ruiz, R. B., & Hernández, P. S. (2016). Cancer chemoprevention by dietary phytochemicals: Epidemiological evidence. *Maturitas*, *94*, 13-19.

29. Tanaka, T., Aoki, R., & Terasaki, M. (2023). Potential chemopreventive effects of dietary combination of phytochemicals against cancer development. *Pharmaceuticals*, *16*(11), 1591.

30. Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020). Phytochemicals in cancer treatment: From preclinical studies to clinical practice. *Frontiers in pharmacology*, *10*, 1614.

31. Rizeq, B., Gupta, I., Ilesanmi, J., AlSafran, M., Rahman, M. M., & Ouhtit, A. (2020). The power of phytochemicals combination in cancer chemoprevention. *Journal of Cancer*, *11*(15), 4521.

32. Boța, M., Vlaia, L., Jîjie, A. R., Marcovici, I., Crişan, F., Oancea, C., & Moacă, E. A. (2024). Exploring synergistic interactions between natural compounds and conventional chemotherapeutic drugs in preclinical models of lung cancer. *Pharmaceuticals*, *17*(5), 598.

33. Wang, H., Oo Khor, T., Shu, L., Su, Z. Y., Fuentes, F., Lee, J. H., & Tony Kong, A. N. (2012). Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*, *12*(10), 1281-1305.

34. Naujokat, C., & McKee, D. L. (2021). The "Big Five" phytochemicals targeting cancer stem cells: Curcumin, EGCG, sulforaphane, resveratrol and genistein. *Current medicinal chemistry*, *28*(22), 4321-4342.

35. Meeran, S. M., Ahmed, A., & Tollefsbol, T. O. (2010). Epigenetic targets of bioactive dietary

components for cancer prevention and therapy. *Clinical epigenetics*, *1*(3), 101-116.

36. Zoi, V., Galani, V., Lianos, G. D., Voulgaris, S., Kyritsis, A. P., & Alexiou, G. A. (2021). The role of curcumin in cancer treatment. *Biomedicines*, *9*(9), 1086.

37. Devan, A. R., Nair, B., & Nath, L. (2022). Translational phytomedicines against cancer: Promise and hurdles. *Advanced Pharmaceutical Bulletin*, *13*(2), 210.

38. Li, Y., Zhang, T., Korkaya, H., Liu, S., Lee, H. F., Newman, B., ... & Sun, D. (2010). Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. *Clinical Cancer Research*, *16*(9), 2580-2590.

39. Rudzińska, A., Juchaniuk, P., Oberda, J., Wiśniewska, J., Wojdan, W., Szklener, K., & Mańdziuk, S. (2023). Phytochemicals in cancer treatment and cancer prevention—review on epidemiological data and clinical trials. *Nutrients*, *15*(8), 1896.